Krystal Biotech is a publicly traded corporation listed on the Nasdaq Global Select Market under the ticker symbol KRYS. As a public entity, its shares are bought and sold by individual retail participants and massive institutional investment firms alike during normal trading hours. The company is bound by strict regulatory reporting standards, requiring it to file comprehensive quarterly and annual financial statements, proxy statements, and disclosure updates with the United States Securities and Exchange Commission. This public standing provides the enterprise with access to deep capital markets, enabling it to fund expensive, large-scale clinical trials and global commercial infrastructure expansions while ensuring complete transparency for its broad stakeholder base.